Skip to content

The Association of Endothelial Dysfunction and Cardiac Allograft Vasculopathy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00173914
Enrollment
100
Registered
2005-09-15
Start date
2003-03-31
Completion date
Unknown
Last updated
2005-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Transplantation

Keywords

1. Transplant vasculopathy, 2. Endothelial dysfunction, 3. Myocardial perfusion imaging, 4. Intravascular vascular ultrasound

Brief summary

Progressive cardiac allograft vasculopathy (CAV) is a serious complication in long-term survivors after heart transplantation. Therefore, we hypothesize that CAV is a diffuse and progressive process, and endothelial function may play an important role in predicting clinical outcome after heart transplantation. Therefore, this single-blinded study is designed to evaluate endothelial function, microvascular flow response and morphology of coronary artery in cardiac allografts, 1. The simultaneous use of IVUS and Doppler wire instrumentation in different pharmacological stress; 2. Tl-201 SPECT (dipyridamole stress/rest); to evaluate the correlation of endothelial function, coronary morphology change and Tl-201 dipyridamole stress myocardial perfusion image.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1\. Heart transplant receipients who undergoing the coronary angiographic follow-up as standard protocols.

Exclusion criteria

1. Acute illness conditions including infection, congestive heart failure (NYHA Fc III, IV), etc. 2. Coronary angiographic finding: coronary stenosis\>30% (as grade III, IV by Klauss V et al, Am J Cardiol 1995; 76:463-6). 3. Creatinine \>3.0 mg/dl

Countries

Taiwan

Contacts

Primary ContactChii-Ming Lee, MD, phD
cmlee@ha.mc.ntu.tw886-2-23123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026